Cargando…
Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD) is a progressive and lethal disease caused by mutations of the dystrophin gene. Currently no cure exists. Stem cell therapies targeting DMD are challenged by limited engraftment and rejection despite the use of immunosuppression. There is an urgent need to introduce...
Autores principales: | Siemionow, Maria, Cwykiel, Joanna, Heydemann, Ahlke, Garcia, Jesus, Marchese, Enza, Siemionow, Krzysztof, Szilagyi, Erzsebet |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960489/ https://www.ncbi.nlm.nih.gov/pubmed/29546607 http://dx.doi.org/10.1007/s12015-018-9807-z |
Ejemplares similares
-
Intraosseous transplant of dystrophin expressing chimeric (DEC) cells improves skeletal muscle function in mdx mouse model of Duchenne muscular dystrophy
por: Malik, Mohammad, et al.
Publicado: (2021) -
Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle's function in Duchenne muscular dystrophy
por: Siemionow, Maria, et al.
Publicado: (2021) -
Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx Mouse Model of Duchenne Muscular Dystrophy
por: Siemionow, Maria, et al.
Publicado: (2019) -
Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy
por: Siemionow, M., et al.
Publicado: (2018) -
Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up
por: Heydemann, Ahlke, et al.
Publicado: (2023)